Figure 2From: Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritisCox proportional hazard model to estimate the rates of discontinuation according to CYP2C19 phenotype (Hazard Ratio = 0.432 for each incremental change in phenotype, 95% Confidence Interval 0.237 to 0.790, P = 0.006 after adjustment for current leflunomide dose, continuation of triple therapy and positive rheumatoid factor at diagnosis).Back to article page